...We Welcome You To The Resverlogix HUB On AGORACOM!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders

Quarterly MD&A should be up today.

"The Corporation also announces that it expects to file its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2018 with Canadian securities regulatory authorities on September 14, 2018. These materials will be available on the Resverlogix website, and on SEDAR, shortly after being filed."

Share
New Message
Please login to post a reply